(IN BRIEF) Voydeya (danicopan), a first-in-class oral Factor D inhibitor, has been recommended for marketing authorization in the European Union…
(IN BRIEF) Soliris (eculizumab) has received approval in China for the treatment of adult patients with neuromyelitis optica spectrum disorder…